All In Biotech

Drug Trial Radar · NCT05771584

Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Gastric Cancer

A Phase 2 Study to Evaluate the Safety and Immunological Efficacy of Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Patients With HER2 Expressing Gastric Cancer (CORNERSTONE-003)

Last checked: Nov 19, 2026Latest source record: Jul 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

24

Actual

Start

Jul 4, 2023

Primary completion

Feb 9, 2027

Study completion May 31, 2027

Sponsor

Lead sponsor
Aston Sci. Inc.Industry
Sponsor type
Industry
First posted
Mar 16, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this early proof-of-concept study to evaluate the safety and immunologic efficacy of AST-301 in gastric cancer patients with HER2 expression (including both HER2 low expression and overexpression) who have completed the standard adjuvant treatment (including those who discontinued the standard adjuvant treatment due to intolerance). Participants will be randomized 1:1 to either Arm 1 (Q3W, 3 cycles), or Arm 2 (Q3W, 6 cycles) of the study. Safety Monitoring Committee (SMC) will oversee safety of study at 25% (6 participants), 50% (12 participants), and 75% (18 participants) of participants receive at least 1 dose of AST-301 and survival follow up will be performed to determine disease-free survival (DFS).

Conditions

  • Gastric Cancer

Interventions

  • AST-301Drug

    100 μg

  • rhuGM-CSFDrug

    100 μg

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with treatment-related adverse events as assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE] version 5.0.Time frame: up to 20 weeks
  2. Immunologic efficacy of AST-301 immunizationTime frame: 52 weeks

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Kaohsiung Medical University Chung-Ho Memorial Hospital

    Kaohsiung City, Taiwan

  • China Medical University Hospital

    Taichung, Taiwan

  • Taichung Veterans General Hospital

    Taichung, Taiwan

  • Chi Mei Medical Center

    Tainan, Taiwan

  • Taipei Veterans General Hospital

    Taipei, Taiwan

  • Chang Gung Memorial Hospital Linkou

    Taoyuan, Taiwan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.